Rosuvastatin Calcium [147098-20-2]

Li Y, Wang Q, Zhou J, et al. Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I. Eur J Pharmacol. 2013 Dec 10;723C:23-28. [Epub ahead of print]. PMID: 24333476. Luo B, Li B, Wang W, et al. Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model. Cardiovasc Drugs Ther. 2013 Nov 20. [Epub ahead of print]. PMID: 24254031. Gan J, Li P, Wang Z, et al. Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway. Exp Ther Med. 2013 Oct;6(4):899-903. PMID: 24137286. Hu X, Sun A, Xie X, et al. Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats. J Cardiovasc Pharmacol Ther. 2013 Mar;18(2):162-76. PMID: 23139358. Pignatelli P, Carnevale R, Di Santo S, et al. Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation. Biochem Pharmacol. 2012 Dec 15;84(12):1635-42. PMID: 23022230. Laumen H, Skurk T, Hauner H. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008 Feb;196(2):565-73. PMID: 17692320. Holdgate GA, Ward WH, McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans. 2003 Jun;31(Pt 3):528-31. PMID: 12773150. Izumi S, Nozaki Y, Maeda K, et al. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos. 2015 Feb;43(2):235-247. PMID: 25414411.